<DOC>
	<DOCNO>NCT02079207</DOCNO>
	<brief_summary>This study assess Immunogenicity safety 13-valent Pneumococcal Conjugate Vaccine compare 23-valent Pneumococcal Polysaccharide Vaccine . All participant naïve Pneumococcal vaccine .</brief_summary>
	<brief_title>Study Immunogenicity Safety 13-valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy Male Female adult 50 year age screening . The subject understand requirement study voluntarily consent participate study . The subject willing use birth control measure entire study duration negative urine hCG ( Human Chorionic Gonadotrophin ) test screen woman presume reproductive potential . Known hypersensitivity component pneumococcal vaccine Any confirm suspected immunosuppressive immunodeficient condition include leukemia , multiple myeloma , lympoma , Hodgkin 's disease , etc . History autoimmune disease include multiple sclerosis ( MS ) , lupus , polymyositis , dermatomyositis , Hashmoto 's thyroiditis , Sjogren 's syndrome , rheumatoid arthritis Functional anatomic asplenia Coagulation disorder contraindicate IM ( intramuscular ) vaccination Use immunosuppressive therapy within precede 3 month include anticancer chemotherapy radiation therapy medication cyclophosphamide , 6mercaptourine , azathioprine , methotrexate , steroid , cyclosporine A , rapamycin , leflunomide , TNFα antagonist ( For corticosteroid , mean prednisone , equivalent dose ≥ 15mg/day . Inhaled topical steroid allow . ) Serious chronic disorder include metastatic malignancy , severe chronic obstructive pulmonary disease require supplemental oxygen , endstage renal disease without dialysis , clinically unstable cardiac disease , impaired immune function . Any licensed vaccine ( include diphtheria toxoid ) administer within 1 month prior receipt study vaccine schedule receive license vaccine ( include diphtheria toxoid ) within 1 month follow receipt study vaccine . Subject receive diphtheria toxoid within 6 month prior receipt study vaccine plan receive diphtheria toxoid full period study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>